Medical

HRAS

Also found in: Dictionary, Financial, Acronyms, Encyclopedia, Wikipedia.

HRAS

A gene on chromosome 11p15.5 belonging to the Ras oncogene family, the protein products of which bind GTP and GDP, have intrinsic GTPase activity, and play key roles in signal transduction. HRAS cycles between de- and re-palmitoylation, a reaction that regulates its rapid exchange between the plasma membrane and the Golgi apparatus.

Molecular pathology
Defects in HRAS are associated with an increased risk of bladder cancer, Hürthle cell carcinoma of thyroid, and oral squamous cell carcinoma. HRAS mutations cause faciocutaneoskeletal syndrome and congenital myopathy with excess of muscle spindles—a variant of Costello syndrome.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in
References in periodicals archive
All reported the key to getting members to complete an HRA is finding the right incentives and that the HRA is only the beginning of a broader member conversation.
The process of implementing online HRAs requires that employers provide electronic eligibility files to the HRA administrators.
Employers that offer regular workplace coverage can also set up another type of HRA account -- limited to $1,800 a year -- that will allow workers to get additional benefits such as dental and vision care.
To be eligible to provide a qualified small employer HRA, an employer must not be an "applicable large employer" (ALE), defined by Sec.
The guidance further addresses the timing, format, and contents of a required written notification of the HRA to employees, how employees may prove they have minimum essential coverage (with a model attestation document as an appendix), and substantiation requirements for reimbursed medical expenses.
Due to the positive federal income tax and payroll tax treatment of employer contributions to retirees' HRAs, as described in PLR 201528004, these arrangements can be a valuable benefit.
Kura Oncology, a United States-based biopharmaceutical company, has commenced dosing in the Phase II clinical trial of tipifarnib in patients with locally advanced tumours that carry HRAS mutations, it was reported on Tuesday.
Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.